Can I get coverage through the Bridge if Wegovy or Zepbound is already on my Part D formulary for another condition
In the SURPASS-CVOT analysis from early 2026, patients on Tirzepatide showed a lower incidence of kidney-related problems compared to those on other treatments
The relationship between GLP-1 receptor agonists and inflammation remains an active area of clinical investigation, with ongoing studies exploring mechanisms and clinical applications beyond traditional metabolic indications
Palek, J., and Volek, V., Experientia , 20 , 420 (1964)
Possible effect modification by age, sex, diabetes status, glycemic control, obesity, CVD, and other comorbidities, as well as compounds, administration methods, and dosages of GLP-1 RAs should be evaluated